Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables - Other (2019 - 2024)

Historic Receivables - Other for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2024 value amounting to $478000.0.

  • BridgeBio Pharma's Receivables - Other fell 9075.44% to $478000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $478000.0, marking a year-over-year decrease of 9075.44%. This contributed to the annual value of $600000.0 for FY2023, which is 9648.69% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Receivables - Other of $478000.0 as of Q3 2024, which was down 9075.44% from $660000.0 recorded in Q2 2024.
  • BridgeBio Pharma's 5-year Receivables - Other high stood at $235.5 million for Q1 2024, and its period low was $462000.0 during Q1 2021.
  • Its 5-year average for Receivables - Other is $23.4 million, with a median of $8.8 million in 2021.
  • Per our database at Business Quant, BridgeBio Pharma's Receivables - Other soared by 522056.28% in 2022 and then tumbled by 9648.69% in 2023.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Receivables - Other stood at $8.0 million in 2020, then soared by 146.86% to $19.7 million in 2021, then fell by 13.52% to $17.1 million in 2022, then crashed by 96.49% to $600000.0 in 2023, then decreased by 20.33% to $478000.0 in 2024.
  • Its Receivables - Other was $478000.0 in Q3 2024, compared to $660000.0 in Q2 2024 and $235.5 million in Q1 2024.